Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Google Inc (GOOG) Price & Performance

Bristol-Myers Squibb CoTrade
Google IncTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Google Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.8 (market cap $129.94B), while Google Inc trades at $341.29 (market cap $4.20T). The key difference: Google Inc is far larger — about 32.3× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.

BMYGOOG
Market Cap
$129.94B$4.20T
Sector
HealthTechnology
52-Week High
$65.89$399.06
52-Week Low
$42.60$200.19
Enterprise Value
$163.92B$4.09T
Dividend Yield
3.96%0.26%
Volume
1,511,127

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.

BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.

Google Inc

Alphabet (GOOG) trades at $340.22, down 4.39% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals, with revenue growing from $282.8B in 2022 to $402.84B in 2025 and net income margin expanding to 32.8%. Recent earnings beats and a consensus analyst price target of $431.67 suggest upside potential, though high capital expenditure plans and regulatory scrutiny pose risks.

The outlook remains positive due to robust AI adoption, with Gemini reaching 1 billion users, but investors face headwinds from elevated capex and antitrust investigations. Wall Street sentiment is overwhelmingly bullish, with 86.84% of analysts rating it a buy, highlighting growth prospects amid competitive and regulatory challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Google Inc

Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.

Read more on GOOG